ArticleMolecular therapy. Nucleic acids2026
Hemoglobin inhibits fibroblast-to-cardiomyocyte reprogramming via TLR2/TLR4-dependent chromatin compaction.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Fibroblast-to-cardiomyocyte reprogramming is influenced by signals present in the injured heart. However, the nature of those signals is unclear. The efficacy of fibroblast-to-cardiomyocyte reprogramming was found to be negatively impacted by extracts derived from the freeze-thawing of normal cardiac tissue. Mass spectrometry identified the adult minor beta chain of hemoglobin (Hbb-b2) as the most abundant protein in the extract, prompting investigation of hemoglobin (Hb) as a candidate inhibitory factor. Indeed, Hb was found to suppress fibroblast-to-cardiomyocyte reprogramming by inhibiting the expression of various cardiomyocyte-specific markers and cardiomyocyte formation. Hb is known to interact with TLR2 and TLR4. While inhibition of either receptor was unable to reverse the effects of Hb, inhibition of both TLR2 and TLR4 reversed the suppressive effects of Hb. To clarify the mechanism, assay for transposase-accessible chromatin using sequencing (ATAC-seq) was performed. ATAC-seq revealed that Hb induced widespread transcription factor network remodeling, whereby stress-associated factor networks were induced and latent CEBP/PAR-bZIP networks were suppressed. These effects were localized to a region 500-750 bp upstream of the transcription start site in cardiomyocyte-specific genes. These findings identify Hb as a potential negative regulator of fibroblast-to-cardiomyocyte reprogramming, with implications for cardiac regeneration strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.